Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4863MR)

This product GTTS-WQ4863MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in Follicular lymphoma research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, BTCT4465A(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ4863MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8362MR IVTScrip™ mRNA-Anti-MUC1, hPAM4(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA hPAM4
GTTS-WQ3589MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ102MR IVTScrip™ mRNA-Anti-KDR, 1121B(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA 1121B
GTTS-WQ9546MR IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA J6M0
GTTS-WQ5792MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA cetuximab-IR700
GTTS-WQ5448MR IVTScrip™ mRNA-Anti-tcdA, CDA 1(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CDA 1
GTTS-WQ4512MR IVTScrip™ mRNA-Anti-CXCL10, BMS-936557(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BMS-936557
GTTS-WQ2331MR IVTScrip™ mRNA-Anti-CD200, ALXN6000(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ALXN6000
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW